Plenary Presentation to be Followed by Poster Presentation Highlighting HLD-0915 Clinical Data ...

Arvinas will present Phase 3 VERITAC-2 trial results for vepdegestrant at ASCO 2025, evaluating its effectiveness in breast cancer treatment. Arvinas, Inc. announced that it will present the detailed ...

Artios Pharma Limited ('Artios”), a biopharmaceutical company committed to realizing the therapeutic power of targeting the DNA damage response ('DDR”) in cancer, today announced an upcoming oral ...

Presentation will cover two-year clinical efficacy, immunogenicity and safety dataData will be presented at an oral session on October 17, 2025, followed by a webinar on October 22, 2025, providing ...

Oral presentations will be scheduled in one hour time blocks between 8:45 AM and 1:00 PM in the Campus Center and SAU. Presentations will be grouped by theme or topic area. Presenters will be notified ...

If I am unable to attend my live oral session, can I pre-record a presentation and have this played during the session? No, all oral presentations must be completed during the live session. If you are ...

A very unusual case of lip-based diffuse large B-cell lymphoma (DLBCL) was treated successfully thanks to prompt diagnosis and chemotherapy treatments. Upon seeing a lip lesion, a physician’s first ...

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, ...

- First presentation of topline clinical data from Phase 1 SAD/MAD trial of VG-3927 for the potential treatment of Alzheimer’s disease (AD) - WATERTOWN, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Vigil ...

SAN DIEGO--(BUSINESS WIRE)--Lassen Therapeutics, a clinical stage biotech company developing first-in-class antibody therapeutics targeting interleukin-11 receptor (IL-11R) and interleukin-18 binding ...

- ASGCT presentation demonstrates lipid nanoparticle (LNP) mediated delivery to the eye in the context of editing of the myocilin (MYOC) gene as a potential treatment for glaucoma - - Expands pipeline ...